NEW YORK ( TheStreet) -- CHANGE IN RATINGS:AFLAC ( AFL) was downgraded at Sterne Agee to neutral from buy. Trading near 52-week highs despite negative EPS revision pressure, Sterne Agee said. Altera ( ALTR) was downgraded at Lazard Capital Markets from buy to neutral. Company faces macro growth headwinds, Lazard Capital Markets said. TD Ameritrade ( AMTD) was downgraded at Sterne Agee to neutral. $19 price target. Valuation call, as the stock is up 20% from its November lows, Sterne Agee said. American Express ( AXP) was downgraded at J.P. Morgan from neutral to underweight. $60 price target. Company may struggle to regain its operating leverage, J.P. Morgan said. B/E Aerospace ( BEAV) was downgraded at Deutsche from buy to hold. Valuation call, based on a $55 price target, Deutsche said. Boston Scientific ( BSX) was upgraded at Credit Suisse from neutral to outperform. $7.50 price target. Sales visibility is improving, Credit Suisse said. Celgene ( CELG) was upgraded at Bank of America/Merrill Lynch from neutral to buy. $115 price target. Company can deliver 25% compound annual earnings growth over the next five years, BofA/Merrill said. Cliffs Natural ( CLF) was upgraded at Deutsche Bank from hold to buy. $48 price target. Sector is down, despite higher commodity prices, Deutsche said. Duke Energy ( DUK) was upgraded at UBS to buy from neutral. $70 price target. Attractive risk/reward profile, UBS said. Consolidated Edison ( ED) was downgraded at UBS to sell from neutral. $53 price target. New York politics leads to regulatory interference, UBS said. FMC Technologies ( FTI) was upgraded at Morgan Stanley to overweight. $65 price target. Company is leveraged to better subsea processing and services demand, Morgan Stanley said. Green Mountain ( GMCR) was upgraded at Argus from hold to buy. $50 price target. Company has strong brands and can benefit from higher coffee prices, Argus said. Global Payments ( GPN) was initiated with a buy rating at UBS. $57 price target. Unique asset with difficult to replicate global footprint, UBS said. Hyatt Hotels ( H) was initiated with an outperform rating at BMO Capital Markets. $45 price target. Strong growth potential, BMO said.